BLTE
NASDAQ
US
Belite Bio, Inc - American Depositary Shares
$169,85
▲ +$2,60
(+1,55%)
Vol. 214K
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$5.6B
ROE
-32,5%
D/E
0,00
Beta
-1,43
52W
$49–$162
Consenso Wall Street
14 analisti · Apr 20264
Acquisto forte
9
Compra
1
Mantieni
0
Vendi
0
Vendita forte
92,9%
Rating Compra
Grafico dei Prezzi
Titoli simili
VTRS
Viatris Inc
$14.3B
AXSM
Axsome Therapeutics Inc
$9.2B
TERN
Terns Pharmaceuticals Inc
$4.3B
CORT
Corcept Therapeutics Inc
P/E 34,5
$3.7B
LGND
Ligand Pharmaceuticals Inc
P/E 76,6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671,4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35,8
$4.5B
Utili
Tasso di battuta: 0,0%
Prossimo report
Mag 11, 2026
Stima EPS: $-0,65
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,65 | — | — |
| Dic 2025 | $-0,56 | $-0,70 | $-0,14 |
| Set 2025 | $-0,50 | $-0,65 | $-0,15 |
| Giu 2025 | $-0,43 | $-0,50 | $-0,07 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — | — |
| Utile netto | -$8.7M | -$10.1M | -$14.3M | -$16.3M | -$21.7M | — |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -34.4% | -31.8% | -34.4% | -34.4% | -34.4% | -32.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | — | 24.30 | 24.30 | 24.30 | 24.30 | 24.30 |
Rapporti chiave
ROA (TTM)
-31,2%
P/B
13,3
EPS (TTM)
$-1,52
52W High
$162,00
52W Low
$49,00
$49,00
Intervallo 52 settimane
$162,00
Salute finanziaria
Flusso di cassa libero
-$4.6M
Debito netto
-$156.5M
Liquidità
$157.0M
Debito totale
$510K
Aggiornato al Set 30, 2025
Як BLTE виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Mid-cap Pharmaceuticals ($2B+) · 25 компаній
Оцінка BLTE vs аналоги Pharmaceuticals
P/E
—
▼
0%
sotto
peer
(30,7)
vs Peer
vs Settore
Valore equo
P/S
—
▼
0%
sotto
peer
(6,7)
vs Peer
vs Settore
Sopravvalutato
P/B
13,3
▲
154%
sopra
peer
(5,2)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(3,1%)
vs Peer
vs Settore
Rendimento basso
Прибутковість BLTE vs аналоги Pharmaceuticals
ROE
-32,5%
▼
24%
sotto
peer
(-26,1%)
vs Peer
vs Settore
Debole
Net margin
—
▼
0%
sotto
peer
(-1,5%)
vs Peer
vs Settore
Top livello
Валова маржа
—
▼
0%
sotto
peer
(88,9%)
vs Peer
vs Settore
Top livello
ROA
-31,2%
▼
230%
sotto
peer
(-9,5%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя BLTE vs аналоги Pharmaceuticals
D/E ratio
0,0
▼
100%
sotto
peer
(27,4)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
24,3
▲
598%
sopra
peer
(3,5)
vs Peer
vs Settore
Liquidità forte
Beta
-1,4
▼
342%
sotto
peer
(0,6)
vs Peer
vs Settore
Più volatile
Радар фундаменталів BLTE
BLTE
Mediana peer
Industria
BLTE прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
BLTE vs аналоги: ключові метрики
Principali azionisti
Top 5: 13,09%Darwin Global Management, L…
7,70%
$460.4M
RTW Investments LP
1,82%
$108.8M
Millennium Management Llc
1,42%
$85.0M
RA Capital Management, L.P.
1,10%
$65.8M
Perceptive Advisors Llc
1,05%
$63.0M
Aggiornato al Dic 31, 2025